Association of disease-modifying treatment and anti-CD20 infusion timing with humoral response to 2 SARS-CoV-2 vaccines in patients with multiple sclerosis
G Disanto, R Sacco, E Bernasconi, G Martinetti… - JAMA …, 2021 - jamanetwork.com
Methods| We performed a prospective observational cohort study at the Neurocenter of
Southern Switzerland. Inclusion criteria were a diagnosis of MS (using the 2017 McDonald
criteria); age older than 18 years; and being scheduled for SARS-CoV-2 mRNA vaccine
(mRNA-1273 [Moderna] or BNT162b2 [Pfizer]). 2, 3 Exclusion criteria were medical
treatments influencing response to vaccines other than MS DMTs and a previous
symptomatic laboratory-confirmed SARS-CoV-2 infection. Written informed consent was …
Southern Switzerland. Inclusion criteria were a diagnosis of MS (using the 2017 McDonald
criteria); age older than 18 years; and being scheduled for SARS-CoV-2 mRNA vaccine
(mRNA-1273 [Moderna] or BNT162b2 [Pfizer]). 2, 3 Exclusion criteria were medical
treatments influencing response to vaccines other than MS DMTs and a previous
symptomatic laboratory-confirmed SARS-CoV-2 infection. Written informed consent was …